| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Yoon Yeo | |
| Gaurav Bajaj | |||
| P2860 | cites work | Peritoneal adhesions: etiology, pathophysiology, and clinical significance. Recent advances in prevention and management | Q28214749 |
| Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel | Q33183577 | ||
| A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer | Q33328907 | ||
| Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G | Q33335882 | ||
| Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study | Q33348987 | ||
| Treatment of peritoneal carcinomatosis by targeted delivery of the radio-labeled tumor homing peptide bi-DTPA-[F3]2 into the nucleus of tumor cells | Q33455875 | ||
| Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer | Q34055165 | ||
| Delivery of molecular and cellular medicine to solid tumors | Q34190339 | ||
| Intraperitoneal drug delivery of antineoplastics | Q34315073 | ||
| Nanoparticle-delivered suicide gene therapy effectively reduces ovarian tumor burden in mice | Q34994831 | ||
| Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization | Q36178042 | ||
| Polymers in the prevention of peritoneal adhesions | Q36946247 | ||
| Peritoneal carcinomatosis: patients selection, perioperative complications and quality of life related to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy | Q37090867 | ||
| Clinical impact of abdominal adhesions: what is the magnitude of the problem? | Q37304555 | ||
| Effects of carrier on disposition and antitumor activity of intraperitoneal Paclitaxel | Q37415150 | ||
| Tumor-penetrating microparticles for intraperitoneal therapy of ovarian cancer | Q37415227 | ||
| Peritoneal carcinomatosis of gastrointestinal origin: natural history and treatment options | Q37528436 | ||
| Indications and patient selection for cytoreductive surgery and perioperative intraperitoneal chemotherapy. | Q37583733 | ||
| Evidence-based medicine in the treatment of peritoneal carcinomatosis: Past, present, and future | Q37583768 | ||
| Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer | Q40673230 | ||
| Liposomal daunorubicin overcomes drug resistance in human breast, ovarian and lung carcinoma cells | Q40678726 | ||
| Stage IV ovarian cancer: impact of surgical debulking | Q41313986 | ||
| Biodegradable polymeric microspheres and nanospheres for drug delivery in the peritoneum | Q43887584 | ||
| Hypersensitivity reactions from taxol | Q44119231 | ||
| Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions | Q44524632 | ||
| Pharmacokinetics and tissue distribution of intraperitoneal docetaxel with different carrier solutions | Q44565476 | ||
| Lymphatic transport of liposome-encapsulated agents: effects of liposome size following intraperitoneal administration | Q47220609 | ||
| Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump | Q49062104 | ||
| Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. | Q50512108 | ||
| Prevention of peritoneal adhesions with an in situ cross-linkable hyaluronan hydrogel delivering budesonide. | Q50974344 | ||
| Peritoneal adhesion prevention with an in situ cross-linkable hyaluronan gel containing tissue-type plasminogen activator in a rabbit repeated-injury model. | Q51000502 | ||
| In situ cross-linkable hyaluronan hydrogels containing polymeric nanoparticles for preventing postsurgical adhesions. | Q51018554 | ||
| Intraperitoneal cisplatin and paclitaxel in ovarian cancer. | Q53263238 | ||
| Liposome-encapsulated daunorubicin for PGP-related multidrug resistance. | Q54082721 | ||
| Liposome-mediated modulation of multidrug resistance in human HL-60 leukemia cells | Q54255653 | ||
| Enhanced cytotoxicity of doxorubicin encapsulated in polyisohexylcyanoacrylate nanospheres against multidrug-resistant tumour cells in culture. | Q55482290 | ||
| Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study | Q67520718 | ||
| The route of absorption of intraperitoneally administered compounds | Q71828308 | ||
| Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest | Q73358276 | ||
| Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer | Q73366531 | ||
| Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study | Q73368601 | ||
| Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study | Q73923094 | ||
| Organ distribution of cisplatin after intraperitoneal administration of cisplatin-loaded microspheres | Q74363291 | ||
| Cremophor reduces paclitaxel penetration into bladder wall during intravesical treatment | Q78147256 | ||
| Update in the management of ovarian and cervical carcinoma | Q80671889 | ||
| P433 | issue | 5 | |
| P921 | main subject | drug delivery | Q1392806 |
| P304 | page(s) | 735-738 | |
| P577 | publication date | 2010-03-03 | |
| P1433 | published in | Pharmaceutical Research | Q7180737 |
| P1476 | title | Drug delivery systems for intraperitoneal therapy | |
| P478 | volume | 27 |
| Q28484262 | A novel magnetic nanoparticle drug carrier for enhanced cancer chemotherapy |
| Q35538164 | Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft model |
| Q39377073 | Antitumor effect and pharmacokinetics of intraperitoneal NK105, a nanomicellar paclitaxel formulation for peritoneal dissemination |
| Q34020450 | Association of liposome-encapsulated trivalent antimonial with ascorbic acid: an effective and safe strategy in the treatment of experimental visceral leishmaniasis. |
| Q41893730 | Battling with environments: drug delivery to target tissues with particles and functional biomaterials |
| Q35206023 | Biodistribution and blood clearance of plasmid DNA administered in arginine peptide complexes |
| Q38169195 | Core-shell nanocarriers for cancer therapy. Part I: biologically oriented design rules |
| Q28484446 | Detoxifying antitumoral drugs via nanoconjugation: the case of gold nanoparticles and cisplatin |
| Q43989079 | Development of a nanocrystalline Paclitaxel formulation for HIPEC treatment. |
| Q38183786 | Drug development for intraperitoneal chemotherapy against peritoneal carcinomatosis from gastrointestinal cancer |
| Q28538327 | Exploiting the synergy between carboplatin and ABT-737 in the treatment of ovarian carcinomas |
| Q46931002 | Hyaluronan-binding peptide for targeting peritoneal carcinomatosis. |
| Q35869447 | Hyaluronic acid-based hydrogel for regional delivery of paclitaxel to intraperitoneal tumors |
| Q37346875 | Improved i.p. drug delivery with bioadhesive nanoparticles |
| Q39120205 | Intraperitoneal administration of cisplatin via an in situ cross-linkable hyaluronic acid-based hydrogel for peritoneal dissemination of gastric cancer |
| Q59800743 | Intraperitoneal delivery of NanoOlaparib for disseminated late-stage cancer treatment |
| Q38068493 | Intraperitoneal delivery of nanoparticles for cancer gene therapy |
| Q37640704 | Intraperitoneal delivery of paclitaxel by poly(ether-anhydride) microspheres effectively suppresses tumor growth in a murine metastatic ovarian cancer model |
| Q53380228 | Microniosomes for concurrent doxorubicin and iron oxide nanoparticles loading; preparation, characterization and cytotoxicity studies. |
| Q38104343 | Nanocrystals for the parenteral delivery of poorly water-soluble drugs |
| Q64263658 | Nanoformulation of Talazoparib Delays Tumor Progression and Ascites Formation in a Late Stage Cancer Model |
| Q41936079 | Nanoparticle tumor localization, disruption of autophagosomal trafficking, and prolonged drug delivery improve survival in peritoneal mesothelioma |
| Q36840545 | Near-infrared fluorescent imaging of metastatic ovarian cancer using folate receptor-targeted high-density lipoprotein nanocarriers. |
| Q52915309 | Neutron-Activatable Nanoparticles for Intraperitoneal Radiation Therapy. |
| Q57293166 | Pentagalloyl Glucose and Its Functional Role in Vascular Health: Biomechanics and Drug-Delivery Characteristics |
| Q88718086 | Peritoneal Carcinomatosis Targeting with Tumor Homing Peptides |
| Q36589159 | Poly(ethylene glycol)-block-poly(ε-caprolactone) micelles for combination drug delivery: evaluation of paclitaxel, cyclopamine and gossypol in intraperitoneal xenograft models of ovarian cancer |
| Q47619786 | Pre-clinical evaluation of a themosensitive gel containing epothilone B and mTOR/Hsp90 targeted agents in an ovarian tumor model |
| Q90754497 | Preclinical evaluation of local prolonged release of paclitaxel from gelatin microspheres for the prevention of recurrence of peritoneal carcinomatosis in advanced ovarian cancer |
| Q28255877 | Progress toward in vivo use of siRNAs-II |
| Q35875509 | Protection against TNFα-dependent liver toxicity by intraperitoneal liposome delivered DsiRNA targeting TNFα in vivo |
| Q90259901 | Targeting Cancer Via Resveratrol-Loaded Nanoparticles Administration: Focusing on In Vivo Evidence |
| Q26750451 | The Potential Protective Effects of Polyphenols in Asbestos-Mediated Inflammation and Carcinogenesis of Mesothelium |
Search more.